Last updated on July 2019

Ovarian Autologous-Platelet Rich Plasma Treatment (PRP) in Menopause.

Brief description of study

Autologous ovarian Platelet Rich Plasma (PRP) treatment may enable restoration of the menstrual cycle in menopausal women, and could offer therefore the possibility of pregnancy employing their own oocytes.

Detailed Study Description

The specific prospective clinical investigation, aims to answer whether autologous Platelet Rich Plasma (PRP) administrated into the ovaries can lead to regeneration and reactivation of the ovarian tissue in menopausal women.

PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. Since many years, PRP has been used in several medical conditions in Orthopedics, Dermatology, Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated.

The aim of this study is to evaluate the effectiveness of ovarian PRP injection, in order to rejuvenate and reactivate the ovaries with the ultimate goal of indicating a possible correlation between this mode of treatment and the reproductive effect in menopausal women.

Clinical Study Identifier: NCT03916978

Find a site near you

Start Over

Genesis AC

Athens, Greece
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.